rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RGNX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Capricor, Regenxbio among gainers as White House pulls Trump’s FDA pick
      13h agoSeeking AlphaCAPRRGNX
      Regenxbio at Stifel 2026 Healthcare Conference: catalysts near
      Nov 11Investing.comRGNXSF
      Regenxbio Inc (RGNX) (Q3 2026) Earnings Call Highlights: Dual Gene Therapy Catalysts Near ...

      Regenxbio Inc (RGNX) eyes pivotal sura-vec data this quarter and a Q1 2027 BLA filing for RGX-202, backed by $251 million in cash and runway into late 2027.

      Nov 7Yahoo FinanceRGNX
      Regenxbio: 2 Major Catalysts Could Change The Investment Case (NASDAQ:RGNX)
      Nov 6Seeking AlphaRGNX
      REGENXBIO Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceRGNX
      Mizuho cuts Regenxbio stock price target on pipeline timing
      Nov 6Investing.comRGNX
      Regenxbio Q3 2026 Earnings Call Transcript
      Nov 5BenzingaRGNX
      Regenxbio: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceRGNX
      Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
      Nov 5Yahoo FinanceRGNX
      REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases - Slideshow (NASDAQ:RGNX) 2026-10-22
      Oct 22Seeking AlphaRGNX
      REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
      Oct 21Yahoo FinanceAMDRGNX
      RegenXBio Announces Board Leadership Changes After Resignation

      Detailed price information for Regenxbio Inc (RGNX-Q) from The Globe and Mail including charting and trades.

      Oct 17The Globe and MailRGNX
      Exclusive BAC Article: REGENXBIO; BLA Submisison RGX-202 DMD Q3 2026, Topline Data Ph3 ABBV-RGX-314 Wet-AMD Q4 2026, And Catalysts (NASDAQ:RGNX)
      Oct 5Seeking AlphaRGNX
      Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call

      Mizuho initiated coverage of Regenxbio with an ‘Outperform’ rating and a $22 price target.

      Oct 5Yahoo FinanceRGNXMFG
      Full Transcript: Regenxbio Q2 2026 Earnings Call - Regenxbio (NASDAQ:RGNX)

      Regenxbio (NASDAQ:RGNX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to

      Oct 5BenzingaRGNX
      Mizuho initiates Regenxbio stock coverage with outperform rating
      Oct 5Investing.comRGNX
      Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Benitec Biopharma (BNTC)

      Detailed price information for Benitec Biopharma Ltd ADR (BNTC-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailBNTCRGNX
      H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data
      Sep 28Investing.comRGNX
      Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn

      In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...

      Sep 26Yahoo FinanceRGNXSRPT
      Stifel reiterates Regenxbio stock rating on gene therapy data
      Sep 25Investing.comRGNX
      Why is Regenxbio stock climbing today?
      Sep 25Investing.comRGNX
      Regenxbio stock gains on positive gene therapy trial data
      Sep 25Investing.comRGNX
      REGENXBIO at Morgan Stanley conference: late-stage gene therapy push
      Sep 16Investing.comRGNXMS
      REGENXBIO at 2026 Global Healthcare Conference: pipeline, cash runway
      Sep 15Investing.comRGNX
      Wet Age-Related Macular Degeneration Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Alcon Research
      Sep 12BarchartRGNX
      REGENXBIO to Participate in Upcoming Investor Conferences

      REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

      Sep 8Yahoo FinanceRGNX
      Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
      Sep 5Yahoo FinanceRGNX
      Why is Regenxbio stock rallying today?
      Aug 28Investing.comRGNX
      Regenxbio stock surges on director share purchases
      Aug 28Investing.comRGNX
      Regenxbio director Ciongoli buys $949,381 in RGNX stock
      Aug 28Investing.comRGNX
      H.C. Wainwright cuts Regenxbio stock price target on clinical hold
      Aug 26Investing.comRGNX
      RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

      REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.

      Aug 25Yahoo FinanceRGNX
      Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity (NASDAQ:RGNX)
      Aug 25Seeking AlphaRGNX
      Regenxbio appoints Greg Ciongoli to board of directors
      Aug 25Investing.comRGNX
      REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

      REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr. Ciongoli joins the Board as REGENXBIO prepares to become a global commercial organization. Mr. Ciongoli has extensive experience in biotechnology investing, capital allocation and corporate strategy to support the Company's next phase of growth.

      Aug 25Yahoo FinanceRGNX
      Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street

      Clear Street said the FDA decision would significantly delay Regenxbio’s resubmission of its application and a potential voucher that could bring in additional cash.

      Aug 25Yahoo FinanceRGNX
      FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial

      The update follows the detection of asymptomatic findings in the spine MRIs of five participants enrolled in the CAMPSIITE study.

      Aug 25Yahoo FinanceRGNX
      Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling
      Aug 24Barron'sRGNX
      Regenxbio Stock Sinks 25% Following Surprise Finding in Gene Therapy Trial
      Aug 24Barron'sRGNX
      REGENXBIO Shares Plunge After FDA Places Clinical Hold on RGX-121

      REGENXBIO Inc. (NASDAQ:RGNX) shares tumbled 35% after the U.

      Aug 24Yahoo FinanceRGNX
      Why is Regenxbio stock plunging today?
      Aug 24Investing.comRGNX
      Why Is Regenxbio Stock Falling Monday? - Regenxbio (NASDAQ:RGNX)
      Aug 24BenzingaRGNX
      Safety concerns spur FDA to again halt testing of Regenxbio gene therapy

      Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.

      Aug 24Yahoo FinanceRGNX
      REGENXBIO stock tumbles after FDA clinical hold on MPS II therapy
      Aug 24Investing.comRGNX
      FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

      Aug 24 () - Regenxbio said on Monday the U. Food ‌and Drug Administration has ‌placed its experimental gene therapy for ​Hunter syndrome on clinical hold after spinal scans found abnormalities in five study participants.

      Aug 24Yahoo FinanceRGNX
      Regenxbio halts BLA resubmission for Hunter syndrome therapy
      Aug 24Investing.comRGNX
      Regenxbio Won't Resubmit US FDA Biologics License Application for Hunter Syndrome Therapy; Shares Down Pre-Bell

      Regenxbio (RGNX) does not plan to resubmit the biologics license application for its investigational

      Aug 24Yahoo FinanceRGNX
      Why Did RGNX Stock Crash Today?
      Aug 24Yahoo FinanceRGNX

      This is the newest page. Registered accounts read further back.